Physician profile
Robert Benza
NPI 1912966144
$1,426.81
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,014 · 2020: $163 · 2021: $116 · 2022: $134.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $316.92 | 2019-2021 | |
| Allergan, INC. | $289.99 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $238.67 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $211.33 | 2019-2020 | |
| Alcon Vision LLC | $96.79 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $55.41 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $36.92 | 2022 | |
| Shire North American Group INC | $34.38 | 2019 | |
| Kala Pharmaceuticals, INC. | $28.42 | 2020-2022 | |
| Abbvie INC. | $26.86 | 2022 | |
| Biotissue Holdings INC. | $22.81 | 2019 | |
| Horizon Therapeutics Plc | $15.49 | 2022 | |
| Eyevance Pharmaceuticals LLC | $14.11 | 2020 | |
| Spark Therapeutics, INC. | $13.68 | 2019 | |
| Ocular Therapeutix, INC. | $12.75 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $12.28 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Benza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.